Knowledge and Barriers to Insulin Therapy among Type 2 Diabetes Mellitus Patients from their Perspective

Journal of Chemical Health Risks

دوره 14، شماره 1، خرداد 2024، صفحه 107-116   

نوع مقاله: Original Article

شناسه دیجیتال (DOI): 10.22034/jchr.2024.1999998.1849

نویسندگان

Helen Williams^{* 1}؛ Srinivasan Ranganathan²

¹Research Scholar, Department of Pharmacy Practice, Faculty of Pharmacy, Bharath Institute of Higher Education and Research (BIHER), Chennai, Tamil Nadu, India

²Research Supervisor, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Bharath Institute of Higher Education and Research (BIHER), Chennai, Tamil Nadu, India

چکیده

Due to the progressive nature of type 2 diabetes mellitus (T2DM), insulin therapy will almost always be needed to maintain appropriate glycemic control in the majority of patients. Insulin therapy is unfortunately not implemented right away. Beginning insulin therapy is made more difficult by a number of patient misconceptions and erroneous ideas. To study the barriers and perceptions to insulin therapy in type 2 diabetes patients from their perspective. A descriptive cross-sectional study was conducted from March – September 2023 among 220 type 2 diabetes mellitus patients presenting in the endocrine outpatient department (OPD) at a tertiary healthcare center. A questionnaire inquiring about demographic characteristics, the status of insulin therapy, barriers to insulin therapy, and knowledge about insulin therapy for T2DM was administered during face-to-face interviews. Results: The study included 220 participants; the majority were from the age group 45–60 years (62.72%), females (50.90%), illiterate (20.90%), employed (58.18%), monthly income above 5000 (89.09%), duration of treatment with 2 or more drugs above 5 years (80.90%), and less than 10 years of insulin added to the treatment regimen (67.72%). The commonest barrier to insulin therapy is that it can cause blindness, cardiac arrest, and amputation, followed by a negative impact on working efficiency (70%). Seventy percent thought that insulin had a negative impact on social relationships and a fear of injection. Regarding the use of insulin, patients have a variety of worries and attitudes. Lack of knowledge about the benefits and adverse effects of using insulin, as well as misconceptions about these topics, appear to be important deterrents for diabetes patients from initiating this therapy. 

کلیدواژه‌ها

Type 2 diabetes mellitus؛ Insulin therapy؛ Knowledge؛ Barriers؛ Patient perception

مراجع

1. Victoria H., Thomsen R.W., Henriksen O., Lohse N., 2011. Diabetes in Sub Saharan Africa. Epidemiology and public health implications. 2(1), 2-9.
2. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., 2008. Intensive blood glucose control and vascular outcome in patients with type 2 diabetes. N Engl J Med. 358(24), 2560-72.
3. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., 1995. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent DM: Randomized prospective 6year study. Diabetes Res Clin Pract. 28(2), 103-17.
4. Turner R.C., Cull C.A., Frighi V., Holman R.R., 1999. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS). 281(21), 25-12.
5. Robert A., Al Dawish M., Braham R., Musallam M., Al Hayek A., Al Kahtany N., 2017. Type 2 diabetes mellitus in Saudi Arabia: Major challenges and possible solutions. Curr Diabetes Rev. 13(1), 59–64.
6. Mahabaleshwarkar R., Gohs F., Mulder H., Wilkins N., DeSantis A., Anderson WE., 2017. Patient and provider factors affecting clinical inertia in patients with type 2 diabetes on metformin monotherapy. Clin Ther. 39(8), 1658-70.
7. Goodall G., Sarpong EM., Hayes C., Valentine WJ., 2009. The consequences of delaying insulin initiation in UK type tow diabetic patients failing oral hypoglycemic agent. BMC Endocr Disord. 9(1), 18-19.
8. Batais M., Schantter P., 2016. Prevalence of unwillingness to use insulin therapy and its associated attitudes amongst patients with type 2 diabetes in Saudi Arabia. Prim Care Diabetes. 10 (6), 415–24.
9. Khan H., Lasker SS., Chowdhury TA., 2008. Prevalence and reasons for insulin refusal in Bangladeshi patients with poorly controlled Type 2 diabetes in East London. Diabet Med. 25(9), 1108–11.
10. Karter A.J., Subramanian U., Saha C., 2010. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care. 33(4), 733–5.
11. Hassan H.A., Tohid H., Amin R.M., Long Bidin M.B., Muthupalaniappen L., Omar K., 2013. Factors influencing insulin acceptance among type 2 diabetes mellitus patients in a primary care clinic: A qualitative exploration. BMC Fam Pract. 14, 164.
12. Ross SA., 2013. Breaking down patient and physician barriers to optimize glycemic control in type 2 diabetes. Am J Med. 126, 38–48.
13. Choac N.H., Shawbs J.E., Karurangaa S., Huanga Y., Rocha Fernandesa J.D., Ohlroggea A.W., 2018. Diabetes atlas: Global estimates of diabetes prevalence for 2017 and projection for 2045. Diabetes Res Clin Pract. 138, 271-81.
14. Brunton S.A., Davis S.N., Renda SM., 2006. Overcoming psychological barriers to insulin use in type 2 diabetes. Clin Cornerstone. 8, 19-26.
15. Karter A.J., Subramanian U., Saha C., Crosson J.C., Parker M.M., Swain B.E., 2010. Barrier to insulin initiation: The translating research into project 2010 into action for diabetes insulin starts project. 33(4), 733-5.
16. Haque M., Navsa M., Emerson SH., Dennison CR., Levitt N.S., 2005. Barriers to initiating insulin therapy in patients with type 2 diabetes mellitus in public-sector primary health care centers in Cape Town. S Afr Med J. 95(10), 798-802.
17. Ishii H., Iwamoto Y., Tajima N., 2012. An exploration of barriers to insulin initiation for physicians in Japan: Findings from the Diabetes Attitudes, Wishes and Needs (DAWN) JAPAN study. PLoS One. 7(6), 361-363.
18. Noor SK., Elmadhoun WM., Bushara SO., Almobarak AO., Salim RS., Forawi SA., 2017. Glycaemic control in Sudanese individuals with Type 2 diabetes: Population based study. Diabetes Metab Syndr. 11, 147-151.
19. Awadalla H., Noor SK., Elmadhoun WM., Almobarak AO., Nehad E., Elmak NE., 2017. Diabetes complications in Sudanese individuals with type 2 diabetes: Overlooked problems in sub-Saharan Africa. Diabetes Metab Syndr. 11, 1047-1051.
20. Nadasen DM., Naidoo M., 2014. Patients with type 2 diabetes and difficulties associated with initiation of insulin therapy in a public health clinic in Durban. South African Family Practice. 54(5), 436-440.
21. Yilmaz A., Muharrem AK., Cim A., Palanci Y., Kilinc F., 2016. Factors influencing insulin usage among type 2 diabetes mellitus patients: A study in Turkish primary care. Eur J Gen Pract. 22(4), 255-261.
22. Saleem A., Masood I., Khan TM., Lee A., Insulin perception among insulinnaïve type-2 diabetes mellitus patients in Pakistan. Cogent Medicine. 3,1-2.
23. Mirghani H., 2018. Clinical inertia and barriers to insulin injection among Sudanese patients with Type 2 diabetes mellitus. J Family Med Community Health. 5(4), 158-159.
24. Irving G., Neves A.L., Dambha-Miller H., 2017. International variations in primary care physician consultation time. BMJ Open 7(5), 179-802.
25. Kalra S., Kalra B., 2010. A good diabetes Counsellor ’Cares’: Soft skills in diabetes counselling. Internet. J Health. 11(1), 1-5.
26. Kalra S., Kumar A., 2019. Quinary prevention: Defined and conceptualized. J Pak Med Assoc. 69(12), 1765–1766.
27. Kumar A., Goel M.K., Jain R.B., Khanna P., Chaudhary V., 2013. India towards diabetes control. Australas Med J. 6(10), 524–531.
28. Lee L.J., Li Q., Reynolds M.W., 2011. Comparison of utilization, cost, adherence, and hypoglycemia in patients with type 2 diabetes initiating rapid-acting insulin analog with prefilled pen versus vial/syringe. J Med Econ. 14(1), 75–86.

 

29. Lee W.C., Balu S., Cobden D., Joshi A.V., Pashos C.L., 2006. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 28(10), 1712–1725.
30. Miles P., Kerr D., Richardson T., 2007. Cutaneous problems in insulin. J Med Econ. 76(4), 1765-1766.
31. Mohan V., Shah S., Saboo, B., 2017. Current glycemic status and diabetes related complications among type 2 diabetes patients in India. JAPI. 61, 12–15.
32. Mohan V., Shah S.N., Joshi S.R., 2014. Current status of management, control, complications and psychosocial aspects of patients with diabetes in India. Indian J Endocr Metab. 18, 370–378.
33. Owens D.R., 2013. Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes. Diabetes Technol Ther. 15(9), 776–785.
34. Pantalone K.M., Misra-Hebert A.D., Hobbs T.M., 2018. Clinical inertia in type 2 diabetes management: Evidence from a large, real-world data set. Diabetes Care. 41(7), 113–114.
35. Peyrot M., Barnett A.H., Meneghini L.F., 2012. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 29(5), 682–689.
36. Peyrot M., Rubin R.R., Lauritzen T., 2005. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 28(11), 2673–2679.
37. Polinski J.M., Smith B.F., Curtis B.H., 2013. Barriers to insulin progression among patients with type 2 diabetes. Diabetes Educ. 39(1), 53–65.
38. Rubin RR., 2005. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med. 118, 27–34.
39. Shestakova M., Sharma S.K., Almustafa M., 2007. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart. Curr Med Res Opin. 23(12), 3209–3214.